Data for this report was compiled from Cortellis, the suite of life sciences intelligence solutions from Clarivate Analytics. Cortellis gives you access to the broadest and deepest sources of intelligence across the R&D lifecycle. Drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2019 were selected for analysis; drugs launched prior to 2019 were excluded. The data pull produced a list of drugs which was then manually reviewed based on factors such as the company’s expected approval or launch dates.
Following this manual review, seven drugs to watch for 2019 were determined. Each drug was subsequently researched and evaluated in its individual context, including clinical trial results, regulatory status, the market for each drug (including analysis of competitor drugs) and regulatory designations (e.g., Orphan Drug, Priority Review). Sources used included SWOT analyses compiled by Cortellis editors, biopharma company press releases and other publications (e.g., annual filings), peer-reviewed publications and Cortellis sales data.
New this year, the team leveraged Cortellis Analytics – Drug Timeline & Success Rates (DTSR), an analytic tool that provides a reliable and accurate way to forecast drug timelines and success rates throughout clinical development. The tool applies statistical modeling and machine learning to predict the timeline and probability of success for a drug, enabling improvements in pipeline forecasting and R&D investment decisions.